Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
ADVERTISEMENT FEATUREAdvertiser retains sole responsibility for the content of this article
Late-stage atopic dermatitis treatment on target
With OC459, a first-in-class, oral, once-a-day small molecule for atopic dermatitis, Atopix has a potential winner for this and other type 2 helper T cell–mediated disorders such as severe asthma and related allergic conditions.